Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer. Clinically, over 80% of patients with cancer were at late stage when they were diagnosed. Therefore, it is important for us to find the biomarker that serve as the early prediction of cancer.
The investigators have published that VEGFC over-expressed in non-small cell lung cancer. VEGFC plays a critical role in regulating motility of tumor cells, promotes proliferation of lymphatic endothelial cells and enhances migration and invasion. Investigator found that VEGFC over-expressed in the serum of esophageal cancer patients. Therefore, it is worthwhile to investigate the correlation between VEGFC, clinical lung cancer and esophageal cancer.
MicroRNAs (miRNAs) are conserved, endogenous, small, and noncoding RNA molecules of 21~23 nucleotides that function as post-transcriptional gene regulators. Recent studies indicated that certain microRNAs reduced in cancer patients. Therefore it is important to investigate whether specific microRNA changed in certain kinds of cancer patients.
| Condition |
|---|
|
VEGFC Protein in Serum VEGFC Protein in Non Small Cell Lung Cancer VEGFC Protein in ESCC CTTN Protein in ESCC miR326 in ESCC and Non Small Cell Lung Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Estimated Enrollment: | 250 |
| Study Start Date: | October 2010 |
| Groups/Cohorts |
|---|
| VEGF-C low |
| VEGF-C high |
| miR-326 low |
| miR-326 high |
Eligibility| Ages Eligible for Study: | 50 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
ESCC and NSCLC patients
Inclusion Criteria:
- tumor size > 0.5 cm3
Exclusion Criteria:
- tumor size < 0.5 cm3
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Jen-Liang Su, China Medical University Hospital |
| ClinicalTrials.gov Identifier: | NCT01240369 History of Changes |
| Other Study ID Numbers: | DMR99-IRB-206 |
| Study First Received: | November 11, 2010 |
| Last Updated: | November 12, 2010 |
| Health Authority: | Taiwan: Department of Health Taiwan: Institutional Review Board |
Keywords provided by China Medical University Hospital:
|
VEGFC CTTN miR326 ESCC NSCLC |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Lung Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Squamous Cell |
ClinicalTrials.gov processed this record on May 23, 2013